Technology & Analytics Solutions revenue increased by $93 million, or 6.4%, while Contract Sales & Medical Solutions revenue decreased by $8 million, or 4.2%. This indicates a shift in growth drivers within the company's segments.

Research & Development Solutions' contracted backlog increased from $31.1 billion as of December 31, 2024, to $31.5 billion as of March 31, 2025. This indicates continued demand for clinical research services.

The company incurred $29 million in restructuring costs in Q1 2025, compared to $15 million in Q1 2024, indicating ongoing efforts to streamline operations and reduce overcapacity.

The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the reporting period. This indicates management's confidence in the reliability of financial reporting.

The company continues to take restructuring actions in 2025 to align its resources and reduce overcapacity to adapt to changing market conditions and integrate acquisitions. These actions include consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. These restructuring actions are expected to continue throughout 2025 and into 2026.

A $4 million loss on extinguishment of debt was recognized in connection with an amendment to the credit agreement, indicating active management of the company's debt structure.

The 10-Q states that there have been no material changes from the risk factors previously disclosed in the 2024 Form 10-K. This suggests a stable risk environment or that the company has not identified any new significant risks.

The company is party to legal proceedings, but management does not believe that the resolution of these matters is reasonably likely to have a material adverse effect on the financial statements. However, the outcome could differ from management's expectations.

Approximately 30% of revenues are denominated in currencies other than the U.S. dollar, and changes in foreign currency exchange rates can significantly affect the results of operations. This highlights the ongoing risk associated with international operations.

The Technology & Analytics Solutions segment experienced a 6.4% revenue increase, suggesting a strong competitive position in its market.

The Contract Sales & Medical Solutions segment experienced a 4.2% revenue decrease, potentially indicating increased competition or changing market dynamics in that segment.

The ongoing litigation with Veeva Systems, Inc. highlights the importance of protecting intellectual property and maintaining a competitive edge in the market.

Restructuring costs increased from $15 million to $29 million, indicating ongoing efforts to improve operational efficiency through consolidation and elimination of redundant positions.

Selling, general, and administrative expenses remained consistent year over year, suggesting stable operational cost management.

Cost of revenues increased by $87 million, or 3.5%, consistent with the overall revenue growth. This indicates that the company is managing its cost structure effectively as it expands.

The Technology & Analytics Solutions segment experienced a 6.4% revenue increase, indicating the success of the company's technology-driven offerings.

The ongoing litigation with Veeva Systems, Inc. highlights the importance of protecting intellectual property and maintaining a competitive edge in the market, particularly in technology and data solutions.

IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade Al™, advanced analytics, the latest technologies and extensive domain expertise.

The company repurchased 2.3 million shares for $425 million in Q1 2025, indicating a continued commitment to returning capital to shareholders.

The Board of Directors increased the stock repurchase authorization by $2 billion, demonstrating confidence in the company's future performance and cash flow generation.

The company recognized a $4 million loss on extinguishment of debt, indicating active management of its debt structure to optimize interest rates and maturities.

We are a global leader in protecting individual patient privacy. We use a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes.

Constant currency revenue growth was higher than reported revenue growth, indicating a negative impact from currency fluctuations. This highlights the company's exposure to global market conditions.

The Company has continued to evaluate the effect of this through the first quarter of 2025 and determined that it did not have any material impacts for the current year. The Company will continue to assess the impact of this proposal as countries are actively considering changes to their tax laws to adopt certain parts of the OECD's proposal.

The constant currency revenue growth for the three months ended March 31, 2025 was primarily the result of volume-related increases in clinical services. The constant currency revenue growth was impacted by a decrease in COVID-19 related work.